Advinus Therapeutics CEO Rashmi Barbhaiya On Disruptive Innovation And India's R&D Edge: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Advinus Therapeutics CEO Rashmi Barbhaiya is one of the most visible figures in today's pharmaceutical research in India. Beyond a deep knowledge of life sciences, he is famous for the daring - if not risky - moves that he made nine years ago, when he shifted from his top job in U.S.-based Bristol-Myers Squibb to head Ranbaxy's R&D team, and then spearheaded the research ambitions of India's biggest corporate conglomerate - The Tata group.
You may also be interested in...
To Boost Productivity, India’s Advinus, Takeda Team Up For R&D Across Therapies
Takeda looks to ride on Advinus’ broad early-stage pipeline while also generating new INDs.
Advinus Moves Ahead With Anti-Diabetes Lead As Tata Group Looks For Strategic Allies
The Indian venture is exploring financing options even as its lead molecule shows promise.
Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.